Association between antidepressant drug use during pregnancy and child healthcare utilisation

BJOG: An International Journal of Obstetrics and Gynaecology

Volumn 116, Issue 12, 2009, Pages 1568-1577

  Ververs, T F ^a,b   Van Wensen, K ^c   Freund, M W ^b   Van Der Heide, M ^b   Visser, G H A ^b   Schobben, A F A M ^a,b   De Jong Van Den Berg, L T W ^d   Egberts, A C G ^a,b  

^a UTRECHT UNIVERSITY   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c VGZ Health Insurance Company   (Netherlands)

^d UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Antidepressants; Cardiac intervention; Healthcare utilisation; Paediatrics; Physiotherapy; Pregnancy

Indexed keywords

AMITRIPTYLINE; FLUOXETINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR;

ARTICLE; CARDIOVASCULAR SURGERY; CHILD HEALTH CARE; CONTROLLED STUDY; DRUG USE; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HEART CATHETERIZATION; HEART DISEASE; HUMAN; MEDICAL RECORD; NETHERLANDS; PHYSIOTHERAPY; PREGNANCY OUTCOME; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL;

ANTIDEPRESSIVE AGENTS; CHILD HEALTH SERVICES; COHORT STUDIES; DELIVERY OF HEALTH CARE; DEPRESSIVE DISORDER; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEART DEFECTS, CONGENITAL; HUMANS; INFANT; INFANT, NEWBORN; MALE; MATERNAL-FETAL EXCHANGE; NETHERLANDS; PATIENT ACCEPTANCE OF HEALTH CARE; PREGNANCY; PREGNANCY COMPLICATIONS; PRENATAL EXPOSURE DELAYED EFFECTS;

EID: 70350096516     PISSN: 14700328     EISSN: 14710528     Source Type: Journal    
DOI: 10.1111/j.1471-0528.2009.02292.x     Document Type: Article

References (39)

1. Ververs T, Kaasenbrood H, Visser G, Schobben F, de Jong-van den Berg L, Egberts T. Prevalence and patterns of antidepressant drug use during pregnancy. Eur J Clin Pharmacol 2006 62 : 863 870.
2. Ramos E, Oraichi D, Rey E, Blais L, Berard A. Prevalence and predictors of antidepressant use in a cohort of pregnant women. BJOG 2007 114 : 1055 1064.
3. Bakker MK, Kolling P, van den Berg PB, de Walle HE, de Jong van den Berg LT. Increase in use of selective serotonin reuptake inhibitors in pregnancy during the last decade, a population-based cohort study from the Netherlands. Br J Clin Pharmacol 2008 65 : 600 606.
4. Andrade SE, Raebel MA, Brown J, Lane K, Livingston J, Boudreau D et al. Use of antidepressant medications during pregnancy: a multisite study. Am J Obstet Gynecol 2008 198 : 194 e1 5.
5. Gardarsdottir H, Heerdink ER, van Dijk L, Egberts AC. Indications for antidepressant drug prescribing in general practice in the Netherlands. J Affect Disord 2007 98 : 109 115.
6. Einarson TR, Einarson A. Newer antidepressants in pregnancy and rates of major malformations: a meta-analysis of prospective comparative studies. Pharmacoepidemiol Drug Saf 2005 14 : 823 827.
7. Berard A, Ramos E, Rey E, Blais L, St-Andre M, Oraichi D. First trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosage. Birth Defects Res B Dev Reprod Toxicol 2007 80 : 18 27.
8. Bar-Oz B, Einarson T, Einarson A, Boskovic R, O'Brien L, Malm H et al. Paroxetine and congenital malformations: meta-analysis and consideration of potential confounding factors. Clin Ther 2007 29 : 918 926.
9. Louik C, Lin AE, Werler MM, Hernandez-Diaz S, Mitchell AA. First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med 2007 356 : 2675 2683.
10. Chambers CD, Hernandez-Diaz S, Van Marter LJ, Werler MM, Louik C, Jones KL et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med 2006 354 : 579 587. (Pubitemid 43209105)
11. Wogelius P, Norgaard M, Gislum M, Pedersen L, Munk E, Mortensen PB et al. Maternal use of selective serotonin reuptake inhibitors and risk of congenital malformations. Epidemiology 2006 17 : 701 704.
12. Cole JA, Ephross SA, Cosmatos IS, Walker AM. Paroxetine in the first trimester and the prevalence of congenital malformations. Pharmacoepidemiol Drug Saf 2007 16 : 1075 1085.
13. Kallen B, Olausson PO. Maternal use of selective serotonin re-uptake inhibitors and persistent pulmonary hypertension of the newborn. Pharmacoepidemiol Drug Saf 2008 17 : 801 806.
14. Kallen BA, Otterblad Olausson P. Maternal use of selective serotonin re-uptake inhibitors in early pregnancy and infant congenital malformations. Birth Defects Res A Clin Mol Teratol 2007 79 : 301 308.
15. Diav-Citrin O, Shechtman S, Weinbaum D, Wajnberg R, Avgil M, Di Gianantonio E et al. Paroxetine and fluoxetine in pregnancy: a prospective, multicentre, controlled, observational study. Br J Clin Pharmacol 2008 66 : 695 705.
16. Alwan S, Reefhuis J, Rasmussen SA, Olney RS, Friedman JM. Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. N Engl J Med 2007 356 : 2684 2692.
17. Moses-Kolko EL, Bogen D, Perel J, Bregar A, Uhl K, Levin B et al. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. JAMA 2005 293 : 2372 2383. (Pubitemid 40676760)
18. Buitelaar JK, Huizink AC, Mulder EJ, de Medina PG, Visser GH. Prenatal stress and cognitive development and temperament in infants. Neurobiol Aging 2003 24 Suppl. 1 : S53 60 Discussion S7-8.
19. Rogal SS, Poschman K, Belanger K, Howell HB, Smith MV, Medina J et al. Effects of posttraumatic stress disorder on pregnancy outcomes. J Affect Disord 2007 102 : 137 143.
20. Koopmans GT, Donker MC, Rutten FH. Length of hospital stay and health services use of medical inpatients with comorbid noncognitive mental disorders: a review of the literature. Gen Hosp Psychiatry 2005 27 : 44 56.
21. Chung EK, McCollum KF, Elo IT, Lee HJ, Culhane JF. Maternal depressive symptoms and infant health practices among low-income women. Pediatrics 2004 113 : e523 9.
22. Mandl KD, Tronick EZ, Brennan TA, Alpert HR, Homer CJ. Infant health care use and maternal depression. Arch Pediatr Adolesc Med 1999 153 : 808 813.
23. Bartlett SJ, Krishnan JA, Riekert KA, Butz AM, Malveaux FJ, Rand CS. Maternal depressive symptoms and adherence to therapy in inner-city children with asthma. Pediatrics 2004 113 : 229 237.
24. Health NCfM. Guideline no. 45: Antenatal and Postnatal Mental Health. London : National Institue for Health and Clinical Excellence, 2007.
25. Hampton T. Antidepressants and pregnancy: weighing risks and benefits no easy task. JAMA 2006 295 : 1631 1633.
26. Zeskind PS, Stephens LE. Maternal selective serotonin reuptake inhibitor use during pregnancy and newborn neurobehavior. Pediatrics 2004 113 : 368 375.
27. Noorlander CW, Ververs FF, Nikkels PG, van Echteld CJ, Visser GH, Smidt MP. Modulation of serotonin transporter function during fetal development causes dilated heart cardiomyopathy and lifelong behavioral abnormalities. PLoS ONE 2008 3 : e2782.
28. Cohen LS, Altshuler LL, Harlow BL, Nonacs R, Newport DJ, Viguera AC et al. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA 2006 295 : 499 507. (Pubitemid 43200344)
29. Minkovitz CS, Strobino D, Scharfstein D, Hou W, Miller T, Mistry KB et al. Maternal depressive symptoms and children's receipt of health care in the first 3 years of life. Pediatrics 2005 115 : 306 314.
30. Goodwin RD, Chuang S, Simuro N, Davies M, Pine DS. Association between lung function and mental health problems among adults in the United States: findings from the First National Health and Nutrition Examination Survey. Am J Epidemiol 2007 165 : 383 388.
31. Wyman PA, Moynihan J, Eberly S, Cox C, Cross W, Jin X et al. Association of family stress with natural killer cell activity and the frequency of illnesses in children. Arch Pediatr Adolesc Med 2007 161 : 228 234.
32. Kulin NA, Pastuszak A, Sage SR, Schick-Boschetto B, Spivey G, Feldkamp M et al. Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multicenter study. JAMA 1998 279 : 609 610.
33. Oberlander TF, Warburton W, Misri S, Aghajanian J, Hertzman C. Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. Arch Gen Psychiatry 2006 63 : 898 906.
34. Gershon MD, Liu MT. Serotonin and neuroprotection in functional bowel disorders. Neurogastroenterol Motil 2007 19 Suppl. 2 : 19 24.
35. Nulman I, Rovet J, Stewart DE, Wolpin J, Pace-Asciak P, Shuhaiber S et al. Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: a prospective, controlled study. Am J Psychiatry 2002 159 : 1889 1895.
36. Juttmann RE, Hess J, Looman CW, van der Maas PJ. Factors that determine the effectiveness of screening for congenital heart malformations at child health centres. Int J Epidemiol 2000 29 : 113 117.
37. Meyer-Wittkopf M, Simpson JM, Sharland GK. Incidence of congenital heart defects in fetuses of diabetic mothers: a retrospective study of 326 cases. Ultrasound Obstet Gynecol 1996 8 : 8 10.
38. Maher JE, Colvin EV, Samdarshi TE, Owen J, Hauth JC. Fetal echocardiography in gravidas with historic risk factors for congenital heart disease. Am J Perinatol 1994 11 : 334 336.
39. Stumpflen I, Stumpflen A, Wimmer M, Bernaschek G. Effect of detailed fetal echocardiography as part of routine prenatal ultrasonographic screening on detection of congenital heart disease. Lancet 1996 348 : 854 857.